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Abstract Health care expenditures are substantially
increasing within the last two decades prompting the
imperative need for economic evaluations in health care.
Historically, economic evaluations in health care have been
carried out by four approaches: (1) the human-capital
approach (HCA), (2) cost-effectiveness analysis (CEA),
(3) cost-utility analysis (CUA) and (4) cost-benefit analysis
(CBA). While the HCA cannot be recommended because
of methodological shortcomings, CEA and CUA have been
used frequently in healthcare. In CEA, costs are measured
in monetary terms and health effects are measured in a non-
monetary unit, e.g. number of successfully treated patients.
In an attempt to develop an effectiveness measure that
incorporates effects on both quantity and quality of life,
so-called Quality Adjusted Life Years (QUALYs) were
introduced. Contingent valuation surveys are used in cost-
benefit analyses (CBA) to elicit the consumer’s monetary
valuations for program benefits by applying the willing-
ness-to-pay approach. A distinguished feature of CBA is
that costs and benefits are expressed in the same units of
value, i.e. money. Only recently, economic evaluations
have started to explore various spinal interventions par-
ticularly the very expensive fusion operations. While most
of the studies used CEA or CUA approaches, CBAs are
still rare. Most studies fail to show that sophisticated spinal
interventions are more cost-effective than conventional
treatments. In spite of the lack of therapeutic or cost-
effectiveness for most spinal surgeries, there is rapidly
growing spinal implant market demonstrating market
imperfection and information asymmetry. A change can
only be anticipated when physicians start to focus on the
improvement of health care quality as documented by
outcome research and economic evaluations of cost-effec-
tiveness and net benefits.
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Introduction
Recent epidemiological studies have reported a life time
prevalence of low back pain (LBP) of up to 84% [11]. Even
though the rate of those individuals who develop chronic
LBP (cLBP) leading to disability is estimated to be only
about 1%, costs caused by restricted activity and bed days
due to chronic LBP (cLBP) as well as its treatment costs
have become a substantial socioeconomic burden in wes-
tern industrial countries [10, 27, 61]. Related to gross
domestic product (GDP), the total average health expen-
diture share across OECD countries increased from 6.6% in
1980 to 9.0% [range 15.3% (USA) to 6% (South Korea)] in
2005 (http://www.oecd.org/health/healthdata).
A cost-of-illness study of back pain in the Netherlands
estimated the total direct medical costs of back pain at
USD 367.6 million which is about 1.7% of the GDP or
nearly one-sixth of the 1991 health care expenses of the
Netherlands [86]. The major part of direct medical costs,
i.e. USD 200 million, was caused by hospital costs. How-
ever, the total indirect costs were found to be USD
4.6 billion of which USD 3.1 billion were due to absen-
teeism of work and USD 1.5 billion due to disablement
indicating that 93% of the costs due to back pain are
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indirect costs. Coyte et al. [13] found a sum of USD
8.1 billion for Canada in 1994 corresponding to 1.07% of
the GNP. Similar figures were reported in a ‘cost-of-ill-
ness’ study from the UK exploring the socio-economic
costs of back pain [61]. Maniadakis et al. [61] estimates
the direct health care cost of back pain in 1998 to be
£ 1,632 million. Approximately 35% of this cost relates to
services provided in the private sector and therefore is most
likely paid directly by patients and their families. However,
the direct cost of back pain was found to be insignificant
compared to the cost of informal care and the production
losses related to it, which total £ 10,668 million. With
these figures, back pain imposes a greater economic burden
than other diseases such as coronary heart disease,
Alzheimer’s disease, stroke, insulin-dependent diabetes
mellitus, epilepsy, benign prostatic hyperplasia, diabetes,
multiple sclerosis, lower respiratory tract infections, deep
vein thrombosis and pulmonary embolism, depression,
critical limb ischaemia, and migraine [61]. Even though
these results cannot be directly compared to other coun-
tries, they may give an idea of the economic impact of back
pain in western industrial countries.
Spinal surgery for persistent LBP is one of the most
rapidly growing surgical disciplines in medicine substan-
tially increasing health care costs for one of the most
common medical problems. The most frequently performed
spinal interventions are lumbar discectomy for a disc her-
niation, spinal decompression for spinal stenosis and spinal
fusion for degenerative disc disease [85]. A variety of fac-
tors contributed to the rising frequency of spinal surgery
over the last decade. Changes in the population (increasing
super-annuation), technological advances (improved
anaesthetic techniques, pedicle screw fixation devices,
fusion cages), and uncertainty regarding indications, as well
as the financial incentives for surgeons, hospitals and the
implant industry may have synergistic effects [16].
In spite of the frequent use of these interventions, sci-
entific evidence for the most frequently performed spinal is
sparse [85]. Debate is still continuing on the therapeutic
efficacy of these interventions to cure back problems
compared to natural history and non-operative treatment.
Particularly, no convincing evidence can be found to sup-
port the use of spinal fusion over a non-operative cognitive
behavioural treatment approach for degenerative disc dis-
ease [9, 21, 49]. Nevertheless, this intervention is one of
the most frequently performed. The lack of scientific evi-
dence for spinal fusion in degenerative disc disease has
recently prompted the discussion whether spinal fusion
should become a case for restraint [16]. In an area of
limited financial health care resources, there is an
increasing demand not only to analyse the therapeutic
efficacy of the treatment modalities but also to consider
related economic and societal costs.
Theoretical background of economic assessments
To better understand economic evaluations it is necessary
to review two of the most important principles of eco-
nomics. Scarcity is a fundamental fact of life. Economics
can therefore be defined as the study of how people make
choices under conditions of scarcity and of the result of
those choices for society [22]. The scarce resources in
healthcare prompt the urgent need for comprehensive
economic evaluations to efficiently allocate sparse resour-
ces. Fundamental in economics is the cost-benefit principle
indicating that an individual (or a firm or a society) should
take an action if the extra benefit from taking the action is
at least as great as the extra benefit [22].
Economic valuation of public goods
An economic evaluation is a comparison of alternative
actions in terms of their costs and benefits, and the purpose
of economic evaluation is to answer about allocation of
resources [47]. Environmental goods, such as air quality,
water quality and bio-diversity have much in common with
health, in that market failures indicate that government
intervention in the market is often desirable. The fact that
government intervention occurs causes economists to wish
for the benefits of such intervention to be compared with
the costs [37]. Early forms of such cost-benefit analyses
were introduced in the USA during the ‘‘Great Depression’’
of the 1930s. Later on, it has been used more and more in
environmental economics as well as in medical care.
Today these methods have gained increased acceptance
among academic economists as well as policy-makers.
They are widely considered to be versatile and powerful
methodologies for valuing non-traded goods and services
[37]. Particularly for environmental field and public
transport guidelines form the National Oceanic and
Atmospheric Administration (NOAA) have been proposed
on how to conduct such analyses [37, 76].
Economic evaluations in health care
Economic evaluations are made at different levels in the
health care system, i.e. by patients, by doctors, by hospitals
and by third party-payers [47]. The purpose of performing
health economic evaluations must be to provide decision-
makers—be they physicians, health administrators or pol-
iticians—with information that can support their allocation
of scarce resources [2]. Quality of life is an important
economic benefit, something we are willing to pay for,
individually and/or collectively [47]. Since resources are
limited, however, we have to choose among different
interventions, within or outside the healthcare system, that
all have the potential for improvement in quality of life
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[47]. For such evaluations to be useful in the eyes
of decision-makers, the studies must be adapted to the
decision-making context of readers and not only to meth-
odological demands [2].
Historically, several strategies have been applied in
analysing programs with non-monetary effects [82].
Human-capital approach
In 1676, Sir William Petty calculated that better medicine
in England would save 200,000 lives, lives he wished to
value monetarily to argue that the requisite funds would be
well spent [82]. This approach to economic evaluation is
usually referred to as the human-capital approach [6]. In
the standard human-capital approach, it is assumed that the
value of society of an individual’s life is measured by
future production potential, usually calculated as the
present discounted value of expected labour earnings [56].
The human-capital approach cannot be recommended as a
basis for measuring the value of improved health in eco-
nomic evaluations, because (1) it is not rooted in the
theoretical foundations of welfare economics, (2) it dis-
criminates people not in the labour force, since increase in
production are measured as wages earned, and (3) ignores
the intrinsic value of good health and quality of life [6, 7].
Shadow pricing
In shadow pricing, non-monetary effects are valued as the
most nearly comparable prices, e.g. relief from arthritis
pain might be valued as the cost of analgesics [82]. The
money spent on analgesics depends not just on the amount
of arthritic pain but also on the efficacy and production
costs of aspirin and other products. The problem with
shadow pricing is that, too often the most comparable
prices do not adequately reflect the value of the public good
[82].
Cost-effectiveness analyses
The limitations of the human-capital approach led to the
development of cost-effectiveness analyses first published
by Klarman in 1968 [6]. In CEA, costs and effects are
measured in monetary and physical units, e.g. life-years
gained, number of successfully treated patients. The deci-
sion rule in CEA is to maximize the effectiveness for a
given budget and best suited to comparison of alternative
treatments that have the same one-dimensional goal [45].
However, Johannesson [43] argues that cost-effectiveness
analysis is best viewed as a subset of cost-benefit analysis,
where the aim of the analysis is to estimate the cost
function of producing health effects. He also concluded
that to interpret and use cost-effectiveness analysis as a tool
to maximize the health effects for one specified real-world
budget, will be inconsistent with a societal perspective and
is likely to lead to major problems of suboptimization.
However, it is important to note that this method does not
escape the valuation problem (e.g. price per life-year that
society is willing to pay).
Cost minimization analyses
This approach is a special form of cost-effectiveness
analysis and involves a given and agreed outcome [53].
Alternative treatment modalities can then be ranked
according to their costs [74, 75].
Cost-utility analyses
In CUA, costs in monetary terms are related to the non-
monetary benefits of a program. This may be used to build
league tables of medical interventions. These tables show
the different amounts of money that have to be paid to gain
a comparable increment of quality of life by different
medical programs. Thus, CUA lead to a ranking of mea-
sures but is not conclusive about the threshold upon which
a measure still should be performed. Quality adjusted life
years (QALY) are mostly used in CUA as the effect
parameter. In the first investigation, utilities for different
health states are assessed. The utility of perfect health is
rated as 1 whereas the utility of death is rated as 0. The
estimated duration of each health state is then multiplied by
the corresponding utility. By transforming these products
into products of the same amount but assuming a perfect
health state (=1) one receives the QALY for each health
state, which can then be compared. However, several
restrictions of this method have to be considered: (1) util-
ities of the different health states have to remain stable
during the whole life, and (2) the number of living-years a
subject is willing to renounce in order to reach a higher
health state must be independent of the living-time left of
this subject (constant proportional trade-off). Furthermore,
studies using QALYs or life-years gained often lack a
relevant discussion of society’s willingness-to-pay per
QALY or life-years gained [2].
The methodological approach of CEA/CUA analyses as
well as cost assessments was covered in a preceding article
in the European Spine Journal and the interested reader is
referred to this article [84].
Cost-benefit analysis
The primary difference between CBA and CEA/CUA is the
way in which health benefits or outcomes are measured.
In CBAs both costs and health benefits are measured
in monetary units, while CEA/CUA measures health in
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non-monetary units such as life-years gained or quality
adjusted life-years (QUALs) [3]. So far, CBA is not yet
widely used in health-related economic evaluations but
provide theoretical and practical advantages which deserve
more attention.
Methodology of cost-benefit analyses
There are two main approaches for CBA in the health care
sector. The revealed-preference approach investigates the
actual choice that individuals make between health and
wealth (e.g. salary compensation for a more risky job) [6].
The second approach is referred to as contingent valuation
(CV) method. The CV is a survey in which respondents are
asked how much they are hypothetically prepared to pay
(willingness-to-pay, WTP) for different programs [6].
According to Olsen and Smith [65], there are three
theoretical advantages for the application of WTP in health
care: (1) WTP is theoretically founded in welfare eco-
nomics, (2) WTP enables a more comprehensive valuation
of benefits than QALYs’ and (3) the CBA allows to
improve allocative efficiency. In spite of the theoretical and
methodological advantages for WTP surveys, these bene-
fits have not been used effectively so far in public health
policy [65]. Because of the aforementioned advantages
many researchers favour CBA for evaluating healthcare
interventions [3].
Theoretical background
The first fundamental value judgment that is made in wel-
fare economics is known as the Pareto principle, which
states that a change is desirable if it makes some individ-
ual(s) better off without making some other individual(s)
worse off. If price and quantity take anything other than
their equilibrium values, a transaction that will make at least
some people better off without harming others can always
been found [22]. This Pareto efficiency relies on three
conditions: (1) efficient exchange, (2) efficient allocation of
factors, and (3) efficient output choice. It is important to
note that the Pareto principal proposes nothing about the
distribution of goods [44]. Since markets will not always
lead to Pareto efficient outcomes due to market failure (e.g.
monopolies, presence of externalities, imperfect informa-
tion, public goods, etc.), there may be a role for public
intervention apart from pure redistribution of income.
Characteristics
In spite of its use in other areas of public policy, CBA has
not been widely applied in the health and social sectors [17,
52, 63], largely because of the difficulties associated with
placing monetary values on the so-called ‘‘intangible ben-
efits of health and social care provisions’’ [38]. In a
contingent valuation survey, consumers are asked to con-
sider a hypothetical scenario where a market exists for the
benefits of the public good evaluated (e.g. a CV survey
might ask WTP questions for the health benefits of cleaner
air due to some programme) [17]. This scenario proceeds to
the hypothetical contingency that such a market exists to
determine what consumers would be willing to pay [17].
There is an increasing interest in WTP as a measure of
health benefits in recent literature on economic evaluation
in health care [6, 64, 65]. There are several reasons why
WTP is preferred over other methods as mentioned above.
There is a large variation of types of questions being asked
in health care contingent valuation method studies [17].
This and the fact that reporting of the applied methods is
poor and often not transparent make it difficult to classify
and appraise the literature. Many studies focus on meth-
odological contents of CBA and WTP. Since no gold
standard has been established to handle difficulties in
interpreting data as for example due to income effects even
more research in the methodological field will be necessary
[15, 18, 19, 30, 42, 52, 73].
Nevertheless, CBA and WTP have been found to be
valuable approaches to assess patients’ benefits in health
care and it has also been shown that CBA is not inferior in
terms of applicability, comprehensiveness to responders or
test–retest reliability to other techniques for eliciting public
preferences for health care such as CEA/CUA [4–6, 28, 36,
54, 58, 59, 64, 71].
Response formats
Four survey techniques can be used to estimate WTP [24,
70, 77]: (1) open-ended questions (OE), (2) bidding-games
(BG), (3) payment card (PC) and (4) closed-ended ques-
tions (CE). In OE, subjects are asked directly how much
they would be willing to pay for a commodity. In BG,
individuals are asked whether or not they are willing to pay
a certain amount. If the answer is yes the bid is increased
until the respondent is no longer willing to pay. If the
answer is no then the bid is decreased until the respondent
says yes to a certain bid. In PC, respondents are presented
with a choice of cards showing different ranges of amounts
of money. Then they are asked to decide which card rep-
resents the most they would be willing to pay. In CE, a
certain amount to be paid is offered to the respondent who
has to answer whether or not he would be willing to pay
this amount by only saying yes or no. The only information
to be obtained from each individual is whether his or her
maximum WTP is above or below the bid offered.
In about 50 studies systematically reviewed by Ryan et al.
[70], the response rates of 22–99% were found indicating
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varying acceptability. The response rate depended on the
technique used for data assessment. Blumenschein [8]
concluded that the dichotomous choice contingent valuation
method overestimates willingness to pay, but it may be
possible to correct for this overestimation by sorting out
‘‘definitely sure’’ yes responses. Green et al. [32] identified
strong anchoring effects in single referendum questions in
contingent valuation surveys on WTP for public goods that
lead to systematically higher estimated mean responses
from yes/no referendum responses than from open-ended
responses. The application of the WTP technique to health
care has focused on using the PC and CE approaches [70].
Reliability
This is defined as repeatability of results over a given time
and usually assessed as test–retest reliability whereby a
sample of respondents repeats the same exercise after a
short period of time [70]. Ryan et al. [70] noted that
implicit in the measure of reliability is an assumption
that preferences exist (are complete) and are stable over
time which may not necessarily be the case in health care.
Based on an extensive review of CV surveys in health
care, Klose [52] and Ryan et al. [70] have found that
reproducibility is rarely investigated and reveal only
mediocre correlations.
Validity
Three types can be differentiated: (1) content validity refers
to the extent to which a measure takes account of all things
deemed important in the construct’s domain. (2) Criterion
validity or external validity is concerned with whether the
measure adopted measures what the researcher is trying to
measure. (3) Construct validity can be separated in two
types. The convergent validity measures the extent to
which results are consistent with other measures that are
held to measure the same construct. The theoretical internal
validity assesses the extent to which the results are con-
sistent with a priori expectations [70].
An important aspect of content validity is that the
hypothetical CV scenario presents valuation tasks and
choices realistic, e.g. by choosing payment vehicles that
are usual in the health task and choices. The positive
influence of health gain and income on WTP demonstrating
theoretical validity is strongly indicated by several papers
[52].
Sources of bias
Several sources of possible bias are known and discussed
controversially. As contingent valuation methods and
therefore WTP usually work with hypothetical questions, it
is not easy to build a bridge between the hypothetical WTP
and the real WTP [8]. A number of laboratory experiments
have studied this relationship by using dichotomous choice
(yes/no) questions and in most cases hypothetical WTP
exceeded real WTP [8, 46]. The influence of household
income has been highlighted in several papers. A higher
household income has found to be associated with a higher
WTP in some investigations while no association could be
found in others [18, 64].
Another source of disturbance is the starting point bias:
Respondents are influenced by the first number presented.
Literature again allows no definite conclusion on this
problem. While some investigations showed starting point
bias others did not [52]. There is also some evidence
suggesting that patients prefer established procedures over
new ones even if they are equal or better [87].
CBA in health economics
Contingent valuation studies have been used so far in three
scenarios: (1) valuing prevention, (2) valuing treatment and
services, and (3) valuing health states [62]. Most studies
remain in a purely hypothetical scenario which might be
difficult to imagine for majority of patients. Patients are
frequently asked to value a hypothetical treatment with a
given outcome [12, 20, 30, 81, 82, 88].
Although the interest in contingent valuation studies has
substantially increased in many different areas in health-
care [17, 63], only a few studies have been performed in
the field of musculo-skeletal disorders, i.e. cervical
spondylotic myelopathy [50], rheumatoid arthritis [74, 75]
and osteoarthritis [14, 20, 82]. Most of them explored
methodological aspects, and only one study has empirically
assessed the benefits of a surgical intervention, i.e. joint
arthroplasty for knee and hip osteoarthritis in a group of
individuals operated on because of osteoarthritis [14].
Economic evaluations in spinal surgery
Increasing data are gathered on the societal costs and
burden of back pain [61] whereas economic evaluations of
spinal surgery are still sparse [79]. Only recently the con-
cept of cost-effectiveness and cost-benefit was applied to
spinal surgery.
Cost assessment studies
Earlier studies [1, 34, 48, 51, 60, 68] compared the inter-
vention costs of alternative surgical procedure (mainly
spinal fusion) without appropriate treatment control group.
However, many of these studies exhibited methodological
limitations related to study design and assessment of
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economic parameters [79]. Based on a review by Soegaard
[79], three early studies were found to be methodologically
credible [26, 55, 72] but only two provided a formal syn-
thesis of costs and effects [26, 55]. Since the review of
Soegaard [79], additional studies were published which
predominantly focussed on the cost side. These studies
dealt with a comparison of one-level lumbar total disc
arthroplasty (TDA) versus lumbar fusion (i.e. anterior
lumbar interbody fusion with iliac bone crest or BMP,
instrumented posterolateral fusion) [33], one- or two-level
TDA versus circumferential fusion [57], or explored
patients’ demands to the primary health sector based
on a comparison of three post-operative rehabilitation
protocols [79].
An interesting analysis was provided by Polly et al. [66]
who compared lumbar spinal fusion to other surgical pro-
cedures i.e. total knee replacement, total hip replacement,
and coronary artery bypass surgery based on the average
reimbursement costs per SF-36 PCS (physical component
summary). Although this study can be criticized for
methodological limitations and flaws, the calculations
indicate that lumbar fusion compares well to other well-
accepted medical interventions.
Cost-effectiveness studies
With regard to the health care scarce resource formal CEA
and CUA relate to our ambition to select the best available
treatment for the money available and could therefore serve
as a bridge of understanding among clinicians, managers,
healthcare policy-makers and politicians [25]. The first
CEA with an appropriate methodology according to current
standards was provided by Kuntz et al. [55] who compared
the cost and benefits of laminectomy alone and laminec-
tomy with concomitant lumbar fusion (instrumented or
non-instrumented) for patients with degenerative lumbar
spondylolisthesis and spinal stenosis. The costs of the
surgery were $14,700 for laminectomy without fusion,
$21,500 for decompression with non-instrumented fusion,
and $30,200 for decompression with instrumented
fusion (based on data from Boston, 1990–1993). According
to this analysis, laminectomy with non-instrumented fusion
resulted in an additional 42 quality-adjusted days per per-
son over a 10-year period at an incremental cost of $5,900,
yielding an incremental cost-effectiveness ratio of $56,000
per QUALY when compared to laminectomy without
fusion. Laminectomy with instrumented fusion cost an
additional $8,700 (over a 10-year period) per person as
compared with non-instrumented fusion and resulted in one
additional quality-adjusted day with a cost-effectiveness
ratio of $3,112,800 per QUALY. The authors concluded
that non-instrumented fusion not only enhances pain relief,
but also increases costs and complications. Instrumented
fusion is regarded as very expensive compared to the
incremental gain in health outcome.
A further study on lumbar fusion techniques considered
the cost-effectiveness of titanium cages versus femoral ring
allografts for anterior lumbar interbody fusion [23], indi-
cating that titanium cages are not cost-effective.
From a health economic perspective, the evaluation may
not only encompass diagnosis and treatment costs, but must
also consider the societal dimension, i.e. the costs of pro-
duction loss from absenteeism and disability [79]. These
costs by far exceed those of diagnosing and treating the
target disease [31]. More importantly, the CEA should
include a non-surgical control group to add to our under-
standing of the societal impact of the target procedure.
The first full CEA fulfilling theses requirements com-
pared three alternative surgical treatment options with a
non-operative control group (n = 284 patients) for
degenerative disc disease. Fritzell et al. [26] reported that
the surgical group required significantly higher societal
costs than in the nonsurgical group (SEK 704,000 vs. SEK
636,000). The direct cost per patient was significantly
higher for the surgical group (SEK 123,000 vs. SEK
65,200) for the control group. The incremental cost-effec-
tiveness ratio (ICER, for explanation see [84]), illustrating
the extra cost per extra effect unit gained by using fusion
instead of nonsurgical treatment were for improvement (i.e.
much better, better, unchanged, worse) SEK 2,600, for
back pain: SEK 5,200, for disability (ODI): SEK 11,300,
and for return to work: SEK 4,100. The authors concluded
that both direct and indirect 2-year costs were significantly
higher for lumbar fusion compared with non-surgical
treatment but all treatment effects were significantly in
favour of surgery. The probability of lumbar fusion being
cost-effective increased with the value put on extra effect
units gained by using surgery.
A similar study was conducted by Rivero-Arias et al.
[69] assessing the cost-effectiveness of spinal fusion over
an intensive cognitive behavioural rehabilitation pro-
gramme in patients with chronic low back pain. At 2 years,
a significant difference in mean total cost of £3,300 per
patient was observed (£7,830 for the surgery group, and
£4,526 for the intensive rehabilitation group). There was no
significant difference in mean QALYs over the trial period.
The incremental cost-effectiveness ratio was estimated to
be £48,588 pounds per QALY gained. These data indicated
that surgical spinal stabilization may not be a cost-effective
use of scarce healthcare resources.
When we want to allocate resources with regards to the
cost-effectiveness of treatment modalities it is mandatory to
better understand the confounding variables on the cost and
the effect side. In this context, Soegaard et al. [80] were the
first to explore factors influencing cost-effectiveness in a
study comparing posterolateral instrumentation and anterior
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intervertebral support as adjuncts to posterolateral lumbar
fusion. The costs of non-instrumented posterolateral fusion,
instrumented posterolateral fusion and instrumented pos-
terolateral and anterior lumbar fusion averaged DKK
88,285, DKK 94,396, DKK 120,759, respectively. The
authors found that the regimes’ net benefit was significantly
affected by smoking, functional disability in psychosocial
life areas, multi-level fusion and surgical technique but no
correlation was found between treatment costs and treat-
ment effects. An incremental analysis suggested that a
limited probability of posterior instrumentation being cost-
effective, whereas the probability of anterior intervertebral
support being cost-effective increased as willingness-to-pay
per effect unit increases. This study highlighted that patient
characteristics have more influence on cost-effectiveness
than the surgical technique itself.
When we interpret cost-effectiveness data on surgical
procedures we must also consider the follow-up period
which can have a substantial impact on the result as out-
lined by Rivero-Arias et al. [69]. The conclusions could
even be reverted when patients undergoing rehabilitation
instead of surgery require secondary surgery. Similarly, we
should consider the cost-effectiveness of the type of
post-surgical rehabilitation as investigated by Soegaard
et al. [78].
In other areas of spinal surgery, economic evaluations
are still very sparse. Economic data from the Spine Patient
Outcomes Research Trial [83] comparing non-operative
(n = 416) versus surgical treatment (n = 775) for lumbar
disc herniation indicate that the mean difference in QALYs
over 2 years was 0.21 in favour of surgery. Surgery was
more costly than non-operative treatment with regard to the
total direct ($20,237 vs. $5,804) and total indirect costs
($7,089 vs. $3,321). The cost per QALY gained for surgery
relative to non-operative care was $69,403 using general
adult surgery costs and $34,355 using Medicare population
surgery costs. Tosteson et al. [83] concluded that surgery
for lumbar disc herniation was moderately cost-effective
when evaluated over 2 years but the estimated economic
value of surgery varied considerably according to the
method used for assigning surgical costs.
Cost-benefit studies
While the cost-effectiveness and cost-utility of several
spinal interventions has been explored [23, 26, 69, 80, 83],
CBA using the CV approach with WTP is very rare in the
field of spinal surgery. So far, only one study [35]
attempted to clarify the feasibility of a cost-benefit
approach in spinal surgery. In this pilot study, the authors
demonstrated the feasibility of the CV approach with ex
post willingness-to-pay/willingness-to-accept (WTP/WTA)
questions in 115 patients who underwent lumbar fusion,
discectomy, or decompression. The patients were asked to
respond to an ex post questionnaire on their WTP/WTA for
their respective intervention. Additional questions addres-
sed socio-demographics, household income, and clinical
outcome. WTP/WTA was related to the actual intervention
costs as well as clinical outcome and the data were then
combined within a formal CBA framework [35]. Almost
90% of the respondents (105/115) were satisfied or very
satisfied with the treatment, 76.2% considered the surgical
result as good or excellent, and 75.7% would choose the
operation for a given hypothetical treatment cost. The
average costs of lumbar fusion (13,800 €) were almost
twice the costs for lumbar decompression (7,000 €).
Discectomy was least cost intensive (5,200 €). The main
components of cost were wages for personnel and medical
services, while implants accounted for 24.0% of the total
costs in the fusion group. In the fusion group, maximum
WTP was one-fifth lower than the actual procedure costs
(not known to the participants), while WTP exceeded costs
in the discectomy and the decompression group by 37 and
10%, respectively. The individuals’ financial situation was
the strongest predictor for WTP. Pain improvement, pres-
ent pain, duration of hospitalization, and estimated
intervention costs were significant independent predictors
in the expected direction for the WTP. Calculation of net
benefits showed that spinal decompression and discectomy
are both within the realms of being cost-beneficial with
positive net benefits while spinal fusion gave rise to a net
welfare loss. Given a hypothetically average wealth and
monthly household income of Switzerland’s population,
maximum WTP was substantially higher than the actual
intervention costs (fusion: ?55%; decompression: ?47%;
discectomy: ?227%).
This pilot study demonstrated that a CV survey using a
WTP approach is feasible and permits the application of
CBA in spinal surgery. Although the majority of patients
answered the questions in a reasonable fashion, refinement
of the methodological approach are mandatory to improve
reliability and validity. If the preliminary results are
reproduced in a full economic study that also includes
indirect costs, CBA may offer an additional tool to help
decision-makers in the, often tense, relationship between
economics and healthcare [35].
Conclusions and recommendations
The costs for spinal surgery in particular spinal stabiliza-
tion are continuously rising despite a lack of clinical
evidence for the effectiveness of these interventions com-
pared to non-operative treatment [9, 21]. This trend is
perpetuated due to a variety of factors such as demographic
changes, advances in technology, unclear indications, and
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financial incentives for the involved parties may have had
synergistic effects [16]. Despite the increasing use of spinal
interventions, scientific evidence for their therapeutic effi-
cacy compared to natural history and non-operative
treatment is sparse. This is particularly true for instru-
mented fusion for degenerative disc disease, one of the
most costly spinal intervention [29]. The subjective out-
come of patients is highly variable prompting the notion
that market growth cannot be reasonably based on con-
sumer’s demand despite the urge to empower and engage
consumers of health care (consumer-driven health care)
[39–41]. The lack of scientific evidence on one hand is
contrasted by the implant market on the other hand, indi-
cating the presence of substantial market imperfections and
asymmetric information. Porter and Teisberg [67] recently
stressed that the current preoccupation with cost shifting
and cost reduction undermines physicians and patients.
These authors [67] propose a strategy for health care
reform that is market based but physician led focusing on a
value-based competition. With such a competition to
improve results, patients will receive better care, physi-
cians will be rewarded for excellence, and costs will be
contained. According to Porter and Teisberg [67], three
principles should guide this change:
– creating value for the patients, i.e. improve the quality
of care
– organizing medical practice around medical conditions
and care cycles rather than around specialities or
procedure
– measuring results i.e. risk-adjusted outcomes and costs.
Following these principles, Porter and Teisberg feel that
professional satisfaction will increase and current pressures
on physicians will decrease. Unless physicians improve
health and health care value for patients, they will inevitably
face ever-increasing administrative control of medicine [67].
Limited healthcare resources increasingly demand that
evidence is obtained not only on therapeutic efficacy of
treatment modalities but also on costs. It is the task for all
of us to convincingly demonstrate the therapeutic and cost-
effectiveness as well as the net benefit of surgical treat-
ments to improve the quality of spinal health care. More
importantly, physician must take a lead because only
medical teams can improve the value of care which is the
only solution to ailing health systems [67].
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